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Endemic Burkitt lymphoma (eBL) is an aggressive B cell lymphoma and is associated
with Epstein-Barr virus (EBV) and Plasmodium falciparum malaria co-infections. Central
to BL oncogenesis is the over-expression of the MYC proto-oncogene which is caused
by a translocation of an Ig enhancer in approximation to the myc gene. While whole
genome/transcriptome sequencing methods have been used to define driver mutations
and transcriptional dysregulation, microRNA (miRNA) dysregulation and differential
expression has yet to be fully characterized. We hypothesized that both human and
EBV miRNAs contribute to eBL clinical presentation, disease progression, and poor
outcomes. Using sensitive and precise deep sequencing, we identified miRNAs from 17
Kenyan eBL patient tumor samples and delineated the complement of both host and EBV
miRNAs. One human miRNA, hsa-miR-10a-5p was found to be differentially expressed
(DE), being down-regulated in jaw tumors relative to abdominal and in non-survivors
compared to survivors. We also examined EBV miRNAs, which made up 2.7% of
the miRNA composition in the eBL samples. However, we did not find any significant
associations regarding initial patient outcome or anatomical presentation. Gene ontology
analysis and pathway enrichment of previously validated targets of miR-10a-5p suggest
that it can promote tumor cell survival as well as aid in evasion of apoptosis. To examine
miR-10a-5p regulatory effect on gene expression in eBL, we performed a pairwise
correlation coefficient analysis on the expression levels of all its validated targets. We
found a significant enrichment of correlated target genes consistent with miR-10a-5p
impacting expression. The functions of genes and their correlation fit with multiple
target genes impacting tumor resilience. The observed downregulation of miR-10a and
associated genes suggests a role for miRNA in eBL patient outcomes and has potential
as a predictive biomarker that warrants further investigation.
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INTRODUCTION
Endemic Burkitt lymphoma (eBL) is the defining Epstein-Barr
Virus (EBV)-associated B cell malignancy in pediatric patients
in equatorial Africa, and is characterized by overexpression of
the c-myc gene, in the vast majority of cases, due to a t(8:14)
chromosomal translocation (Magrath, 1991; Hecht and Aster,
2000). It has an annual incidence of 5–15 cases in 100,000
children in areas experiencing perennial Plasmodium falciparum
transmission. Both EBV infection and holoendemic P. falciparum
are thought to be etiologically linked to the development of this B
cell cancer (reviewed in Moormann and Bailey, 2016). eBL is an
aggressive lymphoma that can present in a number of different
anatomical locations including the jaw, abdomen, orbital area,
central nervous system, and breast or a combination of these
sites (Mwanda et al., 2004; Ogwang et al., 2008). However, jaw
and abdominal tumors are the most common anatomical sites of
presentation (50–80% of cases) in pediatric eBL (Magrath, 1991;
Buckle et al., 2016).
It has been shown that there are different epidemiological
patterns associated with the clinical presentation of eBL. Children
with jaw tumors tend to be younger and mostly males, while
abdominal BL tumors present more commonly among older
children and are equally distributed between males and females
(Ogwang et al., 2008; Asito et al., 2010). Differences are also
seen in childhood sporadic BL (that is only associated with EBV
in 10–20% of cases) where jaw involvement is rare in favor of
abdominal and nodal masses (Mbulaiteye et al., 2009). Despite
the fact that, eBL has observed clinical and pathologic differences,
most studies view eBL as a single clinical entity and attribute
survival differences to delayed presentation and variability in
treatments (Buckle et al., 2016). Given the epidemiological
differences associated with site of tumor presentation that
is incorporated into staging disease, there may be molecular
differences underlying eBL tumor tropism that have not been
fully elucidated although no significant differences in mRNA
expression were observed in our recent analysis (Kaymaz et al.,
2017).
MicroRNAs (miRNAs) are endogenously expressed,
evolutionarily conserved, small single-stranded non-coding
RNAs of approximately 18–25 nucleotides in length that fine-
tune gene expression (Onnis et al., 2010). In animals, miRNAs
control gene expression in a post-transcriptional manner
predominantly by partial base-pairing to specific sites located
in the 3′ untranslated regions (UTR) of their target mRNAs,
triggering degradation, and/or translational inhibition of the
target gene (Bushati and Cohen, 2007; Ameres and Zamore,
2013). It is estimated that ∼50% of all mammalian protein-
coding genes are under miRNA post-transcriptional regulation
(Bushati and Cohen, 2007; Ameres and Zamore, 2013). Since
their discovery in the nematode in 1993 (Lee et al., 1993), many
miRNAs have been identified, andmore than 2,000 miRNAs have
been described in humans (miRBase release 20; Kozomara and
Griffiths-Jones, 2014). Individual miRNAs typically target many
transcripts thereby potentiating broad transcriptional control
which has conceptually shifted our strategies for targeting
oncogenic pathways.
MicroRNAs are involved in many pathological conditions,
and their aberrant expression is observed in most cancers (Croce,
2009), including lymphomas and nasopharyngeal carcinoma
which is another EBV-associated malignancy (Lee et al., 2016).
The pattern of dysregulated miRNA expression can differentiate
B cell neoplasms and provided candidate diagnostic biomarkers
(Di Lisio et al., 2012). For instance, miR-155 is elevated
and highly expressed in Hodgkin lymphoma while low in
Burkitt and other non-Hodgkin lymphomas (van den Berg
et al., 2003). In BL, miRNA dysregulation has been implicated
in c-myc overexpression where hsa-miR-9 may serve as a
diagnostic biomarker for identifying BL cases lacking the c-
myc translocation (Onnis et al., 2010). Studies have also
identified candidate prognosticmiRNAs in lymphomas including
differential expression of miR-21 in diffuse large B cell lymphoma
(DLBCL), where its overexpression was associated with poor
survival (Li et al., 2015; Zheng et al., 2016). B cell chronic
lymphocytic leukemia (CLL) demonstrates down-regulation and
deletions of certain miRNAs as well (Balatti et al., 2015). Studies
to date, to identify prognostic miRNA biomarkers in eBL are
lacking.
EBV is known to drive the proliferation and survival of
infected B cells by expressing multiple viral oncogenes (Young
and Murray, 2003). Although the virus is present in the vast
majority of eBL tumor cells, its viral genes are no longer expressed
in order to evade immune surveillance, except for EBNA1
required for replication (Sample et al., 1991).More recently, it has
been discovered that the virus expresses numerous viral miRNAs
that function to maintain the virus through the subversion of
the immune system and protection from apoptosis (Seto et al.,
2010; Navari et al., 2014). It has also been demonstrated that EBV
miRNAs are also significant viral contributors to the continued
survival and proliferation of BL cells where viral loss leading
to apoptosis could be compensated by expression of ebv-miR-
BHRF1 subset (Vereide et al., 2014; Piccaluga et al., 2016).
Combined, these viral miRNA effects may have the potential
to worsen prognosis and response to treatment but have yet to
be characterized vis-à-vis eBL survival studies and other clinical
features.
Of note within the context of eBL, malaria has been shown
to induce EBV lytic reactivation (Chêne et al., 2007; Piriou et al.,
2009), is associated with higher frequencies of latently infected
B cells (Moormann et al., 2005; Mulama et al., 2014; Reynaldi
et al., 2016), and has a profound impact on B cell activation
which has yet to be fully understood (reviewed in Moormann
and Bailey, 2016). To improve our understanding of both human
and EBV miRNA within the context of pediatric eBL, we used
next generation sequencing, which allows for a more precise
delineation and quantification of the miRNA complement, as
opposed to hybridization based techniques which are subject
to cross hybridization of known miRNAs. We quantified both
viral and host miRNAs expressed in clinically annotated eBL
jaw and abdominal tumors biopsies collected by fine needle
aspirate from children in western Kenya. Apart from the obvious
tissue difference between the clinical presentations of eBL, we
hypothesized that aberrant miRNA expression may be involved
in molecular differences within these tumors, such as amplified
Frontiers in Microbiology | www.frontiersin.org 2 March 2017 | Volume 8 | Article 501
Oduor et al. MicroRNA and Endemic Burkitt Lymphoma
metabolic processes that could favor survival or be predictive
indicators of poor prognosis. We therefore explored the host
and viral miRNA expression activity in eBL tumors comparing
their expression in survivors and non-survivors. The aberrant
expression patterns of these small regulatory RNAs promise
to be rich in biological information that will improve our
understanding of the possible influence of miRNAs on eBL
patient outcomes.
MATERIALS AND METHODS
Sample Collection and Ethical Approval
We collected 17 Fine Needle Aspirates (FNA) of the primary
tumors from children aged between 5 and 12 years diagnosed
with eBL. The biopsy samples were prospectively collected
between 2009 and 2012, prior to chemotherapy treatment
at Jaramogi Oginga Odinga Teaching and Referral Hospital
(JOOTRH) located in Kisumu City, a regional referral hospital
for pediatric cancer cases in western Kenya. Cytology smears
were stained using Giemsa/May-Grünwald for morphologic
diagnosis. A portion of the biopsy was transferred at the bedside
into RNAlater (Qiagen) and stored at−20◦Cwithin 3 h. Of the 17
eBL FNA tumor samples used for this study, 7 eBL patients had
the jaw tumors while 10 had the abdominal tumors. In support
of the diagnosis, RNA-seq expression profile was congruent as
all FNA samples showed B cell predominance and high levels
of normally associated eBL diagnostic surface markers including,
CD19, CD20, CD10, and CD79A/B (Kaymaz et al., 2017). Ethical
review and approval for this study was obtained from the
Institutional Review Board at the University of Massachusetts
Medical School, USA and the Scientific and Ethical Review Unit
(SERU) at the KenyaMedical Research Institute (KEMRI) Kenya,
and Jaramogi Oginga Odinga Teaching and Referral Hospital
(JOOTRH), Kenya Ministry of Health. Children over the age of
7 years were assented. Parents and legal guardians of the study
participants provided written informed consent.
Small RNA Isolation
Small RNA along with large RNA and DNA was isolated
from FNA primary biopsy tissues stored in RNAlater using the
AllPrep DNA/RNA/protein mini kit according to manufacturer’s
instructions (Qiagen). Small RNA abundance and integrity were
determined after isolation using a Nanodrop spectrophotometer
(Thermo Fisher Scientific, Waltham, Massachusetts, USA) and
an Agilent Bioanalyzer (Agilent Technologies, Santa Clara,
CA), respectively. Only samples of small RNA with a miRNA
concentration>10 ng/µl and RIN (RNA integrity number)>8.0
were considered for small RNA library preparations.
Preparation of MicroRNA Libraries for
Deep Sequencing
Seventeen indexed miRNA libraries were prepared using the
Illumina Truseq Small RNA Library Preparation Kit (Illumina
Inc., San Diego, CA, USA). Procedure for the preparation
of the sequencing libraries were performed according to the
manufacturer’s protocol. Briefly, a 3′-adaptor sequence was first
added to the 3′-end of the small RNA molecule then a 5′ adaptor
sequence was added to the 5′-end of the small RNA. The adaptor
ligated RNA was then reverse transcribed into cDNA, which was
eliminated by adding RNase. The libraries were separated from
adapter dimers by size fractionation in 8% TBE polyacrylamide
gel (Life Technologies, Carlsbad, CA, USA). The 150 bp small
RNA libraries were excised and purified from the gel. We then
used the Agilent High Sensitivity DNAKit (Agilent Technologies,
Colorado Springs, CO, USA) to quantify the molarity and
confirm the size distribution. The 17 Indexed miRNA libraries
were pooled in equimolar concentrations and sequenced on
one lane of an Illumina HiSeq 2000 platform (Illumina Inc.,
San Diego, CA, USA). The fastq files were produced using the
CASAVA pipeline v2.0 (Illumina Inc., San Diego, CA, USA)
and all generated sequence were deposited in NCBI dbGAP
(accession number: phs001282.v2).
Bioinformatic Analysis Pipeline and MiRNA
Expression Profile Generation
Preliminary quality control analysis of the 17 fastq files was
carried out with FASTQC software v0.10.0 (Andrews, 2014).
Cutadapt v1.1 (Martin, 2011) was then used to trim off the
3′-adaptor sequence from the sequencing reads. Novobarcode
(Novocraft)1 was used to de-multiplex the samples based on
the 6-nucleotide barcode that was added to the small RNA
sequencing library of each sample. Reads shorter than 17
nucleotides after adaptor trimming and barcode removal were
discarded. The trimmed reads were then further checked for
the presence of any artificial sequences from the adaptor or
barcode using fastqc. Reads passing all the above filters, including
filtering out ribosomal RNAs, were aligned to the human genome
(hg19) using bowtie (Langmead, 2010). Reads were than aligned
to a concatenated wild type reference genome of EBV and
human [RefSeq ID: NC_007605, GRCh37 (hg19), respectively].
Reads that did not uniquely align to the EBV genome were
discarded to insure unique identity of the EBVmiRNA reads. The
resulting sequences were subjected to our computational pipeline
(Figure S1), which consists of a number of in-house scripts
followed by miRDeep2 (Friedländer et al., 2012) analysis to
determine themiRNA counts for each of the eBL samples. Briefly,
we used the mapper module in miRDeep2 (default settings)
to preprocess the sequencing reads and map to the reference
human or EBV genome producing an arf file, however to identify
the viral miRNAs we included a −f flag to obtain maximum
target detection for the low level viral miRNAs. The miRDeep2
quantifier module (default settings) was then used to determine
the expression counts of both the human and viral miRNAs.
Differential miRNA Expression Analysis
Expression analysis of miRNA-Seq data was performed with the
R/Bioconductor version 3.0 package EdgeR (v2.4.6) (Robinson
et al., 2010), which is designed for use with digital gene expression
data. Count numbers of each miRNA were imported to EdgeR,
log2 transformed, and normalized based on negative binomial
distribution model to account for both technical and biological
variability. Human and EBV miRNAs were analyzed as one
1Available online at: http://www.novocraft.com/ (Accessed November 3, 2016).
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group to control conservatively for multiple comparisons. The
miRNA expression counts normalization involved estimating the
sample-specific normalization factors to rescale the observed
counts using the TMM (trimmed mean of M-values) method
(Supplementary Data Sheet 1). Only miRNAs that had at least
10 counts per million (cpm) reads in all the samples were
analyzed for evidence of differential miRNA expression. This
minimal level helps to ensure that expression difference are
not simply low level statistical noise and of likely biologic
consequence (Kozomara and Griffiths-Jones, 2014). Within
edgeR, p-values were adjusted for multiple testing with the
Benjamini and Hochberg (1995) approach for adjusting the false
discovery rate (FDR).
Validation of miRNA Expression Using
qRT-PCR
MiRNA expression levels were validated by quantitative reverse
transcription polymerase chain reaction (qRT-PCR) using
TaqMan miRNA assay protocol on the BioRad CFX96 Real-
Time System. The experiments were run in triplicates on the 17
miRNA samples sequenced. To normalize the expression levels
of the target miRNA by correcting for the amount of cDNA
loaded to the PCR reaction, we used the comparative Ct method.
All Ct-values were normalized to an endogenous control (U54),
and 1Ct-values were calculated, where 1Ct = Ct (miRNA) −
Ct (U54) (Livak and Schmittgen, 2001; Marabita et al., 2016).
Relative expression values (2−1Ct) were plotted and compared.
To verify mean differences among the groups, the normalized
PCR data was analyzed using the wilcoxon rank test in R. A
two-sided p< 0.05 was considered statistically significant.
Functional and Pathway Enrichment
Analysis of the Validated Target Genes
Controlled by the Differentially Expressed
miRNAs
Since the capacity of miRNA to limit gene expression can result
in functional and phenotypic consequences, we identified the
genes controlled by the aberrantly expressed miRNAs between
the jaw and abdominal eBL tumors. The entrez gene IDs of the
target genes which were controlled by the miRs were imported
into the functional Annotation tool of Database for Annotation,
Visualization and Integrated Discovery (DAVID) version 6.7
(Dennis et al., 2003; Huang et al., 2007). DAVID was used
to provide biological functional interpretation of the validated
targets of the DE miRNA and identifies the most relevant KEGG
pathway and gene ontology (GO) categories, composed of the
genes enriched in the given set, followed by an output of statistical
significance evaluated by the modified Fisher’s exact test p-values
[and corresponding false discovery rate (FDR)], which were
calculated to identify which biological pathways are significantly
enriched in the miRNA target list.
miRNA Target Gene Identification and
Correlation Coefficient Calculation
miRNAs regulate expression of specific genes via hybridization
to mRNA transcripts to promote RNA degradation, inhibit
translation, or both (Behm-Ansmant et al., 2006). To investigate
the biological relevance of the identified miRNA, we identified all
the validated target genes for the DE miRNA using the Validated
Target module of the miRWalk2.0 (Dweep et al., 2011; Dweep
and Gretz, 2015) database. Using mRNA expression data from
a published RNAseq dataset (Kaymaz et al., 2017, accession
number: phs001282.v1) for the eBL patients in this study, pearson
correlation coefficients between a miRNA and its validated
target mRNAs were computed using R statistical programming
language, to determine whether the expression levels of each
miRNA and of its mRNA targets show any correlation. Bootstrap
p-values were calculated with replacement from 10,000 replicates
sampled from all expressed mRNAs.
RESULTS
Clinical Information and Sequencing of the
eBL Samples
To investigate the composition of miRNAs in eBL, we sequenced
small RNAs from 17 primary tumor FNA biopsies collected from
Kenyan children with median age 6.8 years old (Table 1). Of
the eBL patients included in this study, 41% (7/17) presented
predominantly with a unilateral jaw tumor whereas 59%
(10/17) had abdominal masses with no apparent tumors above
the diaphragm. In terms of patient outcomes, two patients
died soon after admission to hospital and prior to receiving
any chemotherapy, seven patients died during the in-hospital
course of chemotherapy, and five patients completed induction-
consolidation therapy and were discharged home. One patient
was admitted with relapse having been previously treated while
two patients were lost to follow-up because they were transferred
to another hospital, therefore their outcomes are unknown
(Table 1). For each of the 17 samples, we generated an average
of 1.4 million reads per library and 2,042 distinct human
TABLE 1 | Clinical and demographic characteristics of eBL patients.
Characteristics Total (N = 17)
Age (years), median (range) 7.5 (5–12)
GENDER, N (%)
Male 11 (64.7%)
Female 6 (35.3%)
TUMOR FNA SITE, N (%)
Jaw 7 (41%)
Abdomen 10 (59%)
IN-HOSPITAL SURVIVAL-STATUS, N (%)
SurvivedU 5 (29.4%)
Died¶ 7 (41.2%)
Relapsed 1 (5.9%)
Died prior to chemotherapy§ 2 (11.8%)
Unknown outcome (patient referred to another hospital) 2 (11.8%)
UeBL patients who completed chemotherapy, were discharged from hospital and still
alive after 2 years of follow-up.
¶Patients who had started chemotherapy but died during the course of treatment.
§eBL patient who died before starting chemotherapy.
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miRNAs and 43 distinct viral miRNAs were detected (Figure S2,
Table S2).
miRNAs Show Similar Pattern of
Expression Without Tumor Subtypes By
Hierarchical Clustering
To evaluate whether tumor miRNAs expression patterns were
suggestive of the existence of eBL subtypes, we performed
unsupervised hierarchical clustering of the expression of all
miRNAs. The overall correlations among eBL samples were
extremely high (r > 0.9, average; Figure 1). The most disparate
eBL samples (eBL_03 and eBL_22 compared to eBL_27 and
eBL_16) still show a high degree of correlation (r = 0.7–
0.8). There was no discernible clustering based on tumor
site designation or in-hospital survival. Similarly, principal
component analysis and multidimensional scaling showed
no discernible separation based on tumor presentation site
(Figure S3). Overall, this suggests that eBL tumors are relatively
homogeneous without overt subtypes nor altered miRNA
expression signatures based on tumor presentation site consistent
with lack of subgroups examining mRNA expression (Kaymaz
et al., 2017).
Differentially Expressed (DE) miRNAs
Relative to Tumor Presentation Site and
In-Hospital Survival
Given eBL tumors showed no distinctive clusters of overall
miRNA expression patterns, we focused our analysis on
the differential expression of individual miRNAs. When
the expression of both human and viral miRNAs was
compared between jaw and abdominal eBL tumor samples,
one miRNA, hsa-miR-10a-5p (log2FC = −2.873, p = 0.0018
and FDR = 7.67e-06), was found to be significantly DE
(Table 2; Table S3). This miRNA showed lower expression
in eBL jaw tumors compared to abdominal tumors
(Figure 2A).
Examining differential expression with regards to in-hospital
survival, we compared the miRNA expression profiles of patients
who died during the course of treatment to patients who
successfully completed chemotherapy and were discharged
(i.e., in-hospital survivors). Our analysis detected only one
significant DE miRNA, hsa-miR-10a-5p (log2FC = −2.935, p =
1.12e-05 and FDR = 0.0013) (Table 3), which was significantly
lower in non-survivors relative to survivors (Figure 2B;
Table S3).
FIGURE 1 | Sample to sample hierarchal clustering of BL tumors based on miRNA expression profiles with highest correlation of variation (CV)-values
(calculated using regularized log transformed all miRNA expression).
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TABLE 2 | Differentially expressed miRNA in eBL jaw tumors compared to abdominal tumors.
miRNA Accession P-value False discovery rate (FDR) Fold change (FC) log2FC Jaw tumor vs. abdominal tumor
hsa-miR-10a-5p MIMAT0000253 7.67e-06 0.001857 −2.873 Down-regulated
FIGURE 2 | (A) A volcano plot displaying the statistically significant (p < 0.01 and FDR < 0.1) results and shows the relationship between the significance of miRNAs
detected and the fold-change between eBL jaw and abdominal tumors. miR-10a-5p showed 2.7-fold lower abundance in the jaw vs. abdominal tumors. The red
colored circles represent miR-10a-5p which is differentially expressed with p < 0.01 and FDR < 0.02. The down-regulated miRNAs are signified by a negative
fold-change value and vice versa. (B) A volcano plot representing the significance of miRNAs (−log of the p-value) vs. the fold change difference in eBL Non-survivors’
vs. Survivors. Hsa-miR-10a-5p was also downregulated in the eBL non-survivors.
TABLE 3 | Differentially expressed miRNA in eBL non-survivors compared to survivors.
miRNA Accession P-value False discovery rate (FDR) Fold change (FC) log2FC Non-survivors vs. survivors
hsa-miR-10a-5p MIMAT0000253 1.12e-05 0.0013 −2.935 Down-regulated
From ourmiRNA sequencing data we observed the expression
of 43 known ebv miRNAs in the eBL tumor cells representing
on average 2.7% with a wide range from 0.01 to 11.9% of all
miRNA expression (Tables S1, S2). None of the viral miRNAs
demonstrated significant association with eBL anatomical tumor
presentation site or patient outcome.
miR-10a-5p Validation by qRT-PCR
To assess the reproducibility and validity of the miR-10a
expression levels by deep sequencing we measured its levels by
qRT-PCR. The wilcoxon rank test confirmed the difference in
expression level for miR-10a-5p between the jaw and abdominal
tumors, and also between eBL survivors and non-survivors (p
= 6.29e-05 and 0.0111, respectively). The boxplot in Figures 3,
4, shows the median distribution levels of the log2 normalized
relative quantity of miR-10a-5p in the eBL tumors. The qRT-
PCR results showed good correlation with sequencing (r = 0.77)
based on a correlation test between qRT-PCRmiR-10a expression
levels and miR-10a expression levels from the sequencing
experiment. Overall, this further validates our sequencing results
(Figure S4).
Gene Ontogeny and Functional Enrichment
of Validated Targets
To investigate the potential functional significance of the DE
miRNA (miR-10a-5p), its validated target genes were identified
from Tarbase (Sethupathy et al., 2006) and miRTarbase (Hsu
et al., 2014) in the validated target module of miRWalk2.0
(Table S3). A total of 437 genes were identified to be targeted
by miR-10a-5p. Of these 251 targets showed appreciable
levels of expression in our samples with a median expression
of>10 cpm.
Gene ontology (GO) function andKEGGpathway enrichment
were performed by mapping the validated target genes of
the DE miRNA to the GO and KEGG database, respectively,
using DAVID (Figures S6, Figure 6). For the two DE miRNAs
between jaw and abdominal tumors, Several KEGG pathways
were identified as significantly enriched (p < 0.05; Figure 6).
The target genes of the down-regulated miR-10a-5p in eBL
non-survivors and jaw tumors, were significantly enriched in
pathways of cancer (hsa05200) p = 0.014, focal adhesion
signaling pathway (hsa04510) p = 0.013, and EBV infection
pathway (hsa05169) p= 0.018.
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FIGURE 3 | qRT-PCR validation of miR-10a-5p expression difference in jaw vs. abdominal tumors. The jitter plot shows the normalized expression values
from the miRNA sequencing experiment. The box plot show the log2 median expression levels of miR-10a-5p, confirmed as downregulated in Jaw tumors, estimated
in terms of normalized fluorescence intensity.
miRNA Target Gene Identification and
Correlation of Expression Profiles between
miR-10a-5p and Its Validated Target Genes
In general target transcript levels, should be impacted by
changes in miRNA levels. Previous miRNA and mRNA target
analysis have noted that the majority of target gene expression
do not show simple negative correlation but rather the most
predominant finding is increased rates of both positive and
negative correlation (Ruike et al., 2008; Wang and Li, 2009).
The role of positive correlations due to positive feed-forward
loops have been increasingly recognized (Friard et al., 2010;
Chen et al., 2011; Zhang et al., 2015). We performed a pairwise
correlation coefficient analysis between miR-10a-5p expression
levels and the expression levels of its 251 validated target
genes with a median count >10 cpm from an RNAseq data
set for the eBL patients. We found five positive and three
negative correlations p < 0.05, which overall, was not significant
based on bootstrapping replicates of random genes. Given
the levels of miR-10a are very low in a number of samples
we examined the upper half (log2miR-10a levels >10) and
lower half (log2miR-10a levels <10) separately to look for
regulation at higher levels of the miRNAs. In this case, we
saw more numerous correlations when the gene was more
highly expressed, 22 genes with significant correlations (P <
0.05), which was more than expected by chance (p = 0.0352)
based on a simulation test on random gene selection. The
lower half showed poor correlation suggesting that at low
levels there is poor regulation and other factors predominant
in determining target levels. Of the validated target gene set,
there are multiple genes with some degree of correlation that
would explainmiR-10a association with patient survival outcome
by impairing apoptotic death, CD59, API5, MDM4, and YY1
showed an inverse relationship with miR-10a levels. Increased
levels of each of these genes could impair apoptotic death
and influence eBL patient prognosis. Positively correlated genes
that would decrease and increase apoptotic death of the tumor
cells include BCL2L13, and PTEN. While only CD59 showed
a significant (P < 0.05) inverse correlation with miR-10a levels
(Figures 5A,B), overall, this analysis suggests that miRNA is
modulating multiple genes in a consistent way that could impair
patient survival.
DISCUSSION
Previous studies, have shown that cancer tumors with different
anatomical sites have unique patterns of miRNA expression
(Lu et al., 2005; Petillo et al., 2009). Using next generation
sequencing and controlling for multiple comparisons, we
identified miR-10a-5p to be DE between the two major eBL
tumor presentation sites, and also uncovered pathways that are
possibly enriched by this DE miRNA. miR-10a-5p expression
was also found to be significantly lower in eBL patients who
did not survive after starting chemotherapy treatment. This
miRNA was downregulated in eBL patients with the jaw
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FIGURE 4 | qRT-PCR validation of miR-10a-5p expression difference in eBL survivors vs. non-survivor tumor samples. The jitter plot shows the normalized
expression values from the miRNA sequencing experiment. The box plot shows the log2 median expression levels of miR-10a-5p, confirmed as downregulated in eBL
non-survivor patients, estimated in terms of normalized fluorescence intensity.
FIGURE 5 | (A) Pearson correlation scatter plot showing a negative correlation between hsa-miR-10a-5p and CD59 expression levels in eBL patients. The horizontal
and vertical axis represents the log2-expression values of the miRNA and mRNA, respectively. These plots show the relationship between hsa-miR-10a-5p expression
and CD59 expression levels in eBL patients based tumor site. (B) Pearson correlation scatter plot showing a negative correlation between hsa-miR-10a-5p and CD59
expression levels in eBL patients based on patient survival outcome. The horizontal and vertical axis represents the log2-expression values of the miRNA and mRNA,
respectively. The plots show the relationship between hsa-miR-10a-5p expression and CD59 expression levels in eBL patients based on patient outcome.
tumor and also in eBL non-survivors with >2.8- and 2.9-fold
decrease, respectively. To gain some insight into the biological
functions deregulated by miR-10a-5p, we identified its validated
targets and used mRNA expression data to add biological
significance by performing a pairwise correlation analysis. We
show that correlated transcription suggests that these genes likely
work together to inhibit apoptosis and minimize sensitivity to
chemotherapy.
In support of miR-10a-5p role in cancer, downregulation
of miR-10a-5p has also been implicated in other cancer
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FIGURE 6 | Significantly enriched signaling pathways of the validated targets of miR-10a-5p.
studies (Jansson and Lund, 2012). Downregulation has been
reported in chronic myeloid leukemia (CML) and associated
with increased cell growth of the CML cells (Agirre et al.,
2008). Experimental re-expression of hsa-miR-10a-5p in CML
cells decreased cell growth, thus supporting the functional role
of hsa-miR-10a in CML disease progression (Agirre et al.,
2008).
The potential relevance of the miR-10a-5p in eBL tumors
can best be discussed by examining its targets and implications
for altering their function. Since the expression of the observed
Frontiers in Microbiology | www.frontiersin.org 9 March 2017 | Volume 8 | Article 501
Oduor et al. MicroRNA and Endemic Burkitt Lymphoma
DE miRNA is downregulated in jaw compared to abdominal
tumors and is associated with poor survival, the dysregulation
of its target genes could lead to significant biologic differences
that may influence patient survival (Yousef and Allmer, 2014).
Our analysis supports that miR-10a-5p is biologically relevant
and that there is a set of targets that potentiate tumor resistance
to apoptosis and chemotherapy. MiR-10a-5p downregulation in
the jaw tumors could lead to hyperactivation of its target CD59
(Helwak et al., 2013), a potent inhibitor of the complement
membrane attack complex. Experimental evidence has shown
that CD59 is effective at protecting cancer cells from antibody
(i.e., rituximab) mediated complement-dependent cytotoxicity
(You et al., 2011). High expression of CD59 has also been
correlated with poor overall survival and progression free
survival in lymphoma patients treated with R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone;
Song et al., 2014). Lack of post-transcriptional regulation of
CD59 due to miR-10a-5p downregulation in eBL patients would
enhance tumor cell survival and possibly increase relapse rates.
We show a significant inverse correlation between miR-10a-
5p and CD59 expression levels in eBL tumors (Figures 5A,B),
pointing to a potentially functional miRNA-mRNA relationship
which could promote tumor cell survival, chemoresistance and
poor outcomes.
Considering the aggressive nature of the defects leading to eBL
development, downregulatedmiR-10a-5p could also promote the
hyperactivation of API5 (apoptosis inhibitor 5), an apoptosis
inhibitory protein, which renders tumor cells resistant to T cell
initiated apoptosis (Noh et al., 2014). API5 has been shown
to impair the cytotoxic effect induced by chemotherapeutic
drugs (Faye and Poyet, 2010), while miR-10a-5p confers post-
transcriptional regulation of API5 gene (Karginov and Hannon,
2013). An inverse correlation was observed between API5 and
miR-10a-5p level, suggesting this interaction may influence
response to treatment and eBL patient survival. We also observed
an inverse relation between miR-10a and MDM4 levels. Given
that miR-10a-5p targets MDM4 and MDM2, inhibitors of p53
(Francoz et al., 2006), this interaction could influence survival of
eBL patients (Leroy et al., 2002; Kishore et al., 2011; Yousef and
Allmer, 2014).
Molecular network analysis enables us to characterize the
most relevant pathways involved in the miRNA targets in silico
(Murray et al., 2010). Human miRNA targets regulated by
an individual miRNA generally constitutes function-associated
molecules. It is therefore plausible that even a small change
in the expression of a single miRNA could affect a wide
range of signaling pathways and networks involved in diverse
biological functions (Murray et al., 2010). Through the
enrichment and function analysis using DAVID database, we
propose that the target genes of the DE miRNA in the
jaw tumor and non-survivors, may lead to the enhancement
of many important biological processes, including positive
regulation of cell proliferation (Figures S5, S6). Enrichment
analysis indicated that the target genes of the identified DE-
miRNA were mainly involved in cancer-related KEGG pathways,
including, focal adhesion signaling, and pathways in cancer
which were significantly enriched as the top most relevant
KEGG pathways. These appear to impact a survival advantage
for tumor cells. FAK (Focal adhesion kinase) signaling has
been associated/related to transformation, metastasis, migration,
and poor outcome (Miyazaki et al., 2003; Benlimame et al.,
2005; Natarajan et al., 2006) in many solid tumors and also
in hematologic malignancies. This pathway is also presumed
to inhibit signaling pathways leading to the activation of
caspase 3 (Sonoda et al., 2000). FAK pathway enrichment by
the targets of miR-10a-5p, as a result of the upregulation
of these genes, would promote apoptotic escape of thus
sustaining tumor cell survival or increased tumor burden.
This pathway enrichment analysis provides insight into the
molecular events that may lead to poor outcome among eBL
patients.
Our observation that eBL tumors express varying levels of
EBV miRNAs suggested a role for EBV non-coding transcripts
in eBL disease progression, as postulated by another group
(Piccaluga et al., 2016). The BHRF1 miRNA cluster has been
shown to strongly potentiate the transforming properties of
EBV (Li et al., 2012; Ma et al., 2016), and have been shown to
downregulate genes that antagonize or prevent B cell growth
(Bernhardt et al., 2016). However, based on our study of
Kenyan eBL patients we were not able to demonstrate any
impact of EBV miRNA on patient outcome or anatomical
location of tumor. It is possible that viral miRNA are important
during B cell transformation but no longer informative after
tumorigenesis.
A limitation of this study is sample size. However, 17 eBL
tumors is comparable to other published studies of miRNA
associations with diagnosis or outcome (Sun et al., 2004).
Nevertheless, the power to detect nuanced differences is modest
and there may be biologically meaningful differences in miRNA
expression that we have not detected. Stochastic noise may have
influenced our findings although we carefully controlled for
significance and false discovery rate. However, larger, multi-site
sample sets are needed to truly validate the functional role of host
and viral miRNA in eBL. The role malaria plays, either directly
or indirectly (Moormann and Bailey, 2016), in aberrant miRNA
expression was not addressed within our study but warrants
investigation. The dynamic mechanisms by which miRNA target
genes and influence cancer progression is clearly an active area of
investigation.
In conclusion, we found evidence for an altered miR-10a-
5p expression pattern between different tumor sites. We show
that there is low expression of miR-10a-5p in eBL patients
presenting with jaw tumors and overall in patients who died. A
significant inverse correlation was observed between miR-10a-5p
and CD59 expression, implying a biologically relevant, functional
miRNA-mRNA target interaction, which would enhance tumor
cell survival and thus render the tumor less sensitive to
chemotherapy. These findings provide novel insight into the
role of miRNA in the pathogenesis of eBL and a basis for
future research on miR-10a-5p and CD59 involvement in eBL
patient outcomes. Understanding how miRNA influence tumor
progression has implications for the development of novel
therapeutic interventions to improve outcomes for children
diagnosed with eBL.
Frontiers in Microbiology | www.frontiersin.org 10 March 2017 | Volume 8 | Article 501
Oduor et al. MicroRNA and Endemic Burkitt Lymphoma
AUTHOR CONTRIBUTIONS
Conception and design of the study: CO, KC, AM, JB. Acquisition
of samples: CO, JO, JMO, AM. Performed the experiments: CO,
YK, MM. Analysis and interpretation of data (e.g., statistical
analysis, biostatistics, computational analysis): CO, MM, YK,
AM, JB. Writing, review, and/or revision of the manuscript: CO,
MM, YK, KC, JO, JMO, AM, JB.
FUNDING
This study was supported by the US National Institutes of Health,
National Cancer Institute R01CA134051, R01CA189806 (AM)
and The Thrasher Research Fund 02833-7 (AM), UMCCTS Pilot
Project Program U1 LTR000161-04.
ACKNOWLEDGMENTS
The authors would like to thank to the Director of KEMRI for
providing permission to publish this study. We would also like
to thank the parents and guardians for enrolling their children in
this study.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmicb.
2017.00501/full#supplementary-material
Supplementary Data Sheet 1 | Normalized expression counts of Human
and EBV miRNAs expressed in eBL tumor.
Figure S1 | Bioinformatic workflow for host and viral miRNA analysis
pipeline (processed raw reads and identified counts of known human and
ebv miRNAs in high-throughput sequencing data).
Figure S2 | Hierarchical clustering of all the host and viral miRNAs
expressed in the eBL tumor cells.
Figure S3 | PCA plots of eBL tumors sites. The sample names were colored
per their groups (red represents the jaw tumors and black represented the
abdominal tumors). The tumor samples don’t show well-defined grouping based
on tumor site in the PCA analysis.
Figure S4 | Pearson correlation scatter plots showing a positive
correlation between qRT-PCR miR-10a-5p expression levels and
miRNA-seq miR-10a-5p expression levels.
Figure S5 | Pearson correlation scatter plots showing the relationship
between hsa-miR-10a-5p expression and its target gene expression in
eBL patients. The blue points represent the eBL patients with the jaw tumors
and the red points represents eBL patients with the abdominal tumors.
Figure S6 | Gene ontologies enriched (Biological processes, Cellular
components and Molecular functions) by the validated target genes of
miR-10a-5p.
Table S1 | Key patient characteristics and small RNA sequence mapping
information.
Table S2 | miRNA differential expression analysis results.
Table S3 | Validated target genes of miR-10a-5p and miRNA-target mRNA
expression correlation coefficients.
REFERENCES
Agirre, X., Jiménez-Velasco, A., San José-Enériz, E., Garate, L., Bandrés, E.,
Cordeu, L., et al. (2008). Down-regulation of hsa-miR-10a in chronic myeloid
leukemia CD34+ cells increases USF2-mediated cell growth. Mol. Cancer Res.
6, 1830–1840. doi: 10.1158/1541-7786.MCR-08-0167
Ameres, S. L., and Zamore, P. D. (2013). Diversifying microRNA sequence and
function. Nat. Rev. Mol. Cell Biol. 14, 475–488. doi: 10.1038/nrm3611
Andrews, S. (2014). FastQC. A Quality Control Tool for High Throughput
Sequence Data. Babraham Bioinformatics. Available online at: http://www.
bioinformatics.babraham.ac.uk/projects/fastqc
Asito, A. S., Piriou, E., Odada, P. S., Fiore, N., Middeldorp, J. M., Long, C., et al.
(2010). Elevated anti-Zta IgG levels and EBV viral load are associated with site
of tumor presentation in endemic Burkitt’s lymphoma patients: a case control
study. Infect. Agent. Cancer 5:13. doi: 10.1186/1750-9378-5-13
Balatti, V., Pekarky, Y., and Croce, C. M. (2015). Role of microRNA in
chronic lymphocytic leukemia onset and progression. J. Hematol. Oncol. 8:12.
doi: 10.1186/s13045-015-0112-x
Behm-Ansmant, I., Rehwinkel, J., and Izaurralde, E. (2006). MicroRNAs
silence gene expression by repressing protein expression and or by
promoting mRNA decay. Cold Spring Harb. Symp. Quant. Biol. 71, 523–530.
doi: 10.1101/sqb.2006.71.013
Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a
practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat.
Methodol. 57, 289–300.
Benlimame, N., He, Q., Jie, S., Xiao, D., Xu, Y. J., Loignon, M., et al.
(2005). FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation
for oncogenic transformation and invasion. J. Cell Biol. 171, 505–516.
doi: 10.1083/jcb.200504124
Bernhardt, K., Haar, J., Tsai, M.-H., Poirey, R., Feederle, R., and Delecluse, H.-J.
(2016). A viral microRNA cluster regulates the expression of PTEN, p27 and of
a bcl-2 homolog. PLoS Pathog. 12:e1005405. doi: 10.1371/journal.ppat.1005405
Buckle, G., Maranda, L., Skiles, J., Ong’echa, J. M., Foley, J., Epstein, M., et al.
(2016). Factors influencing survival among kenyan children diagnosed with
endemic Burkitt lymphoma between 2003 and 2011: a historical cohort study.
Int. J. Cancer 139, 1231–1240. doi: 10.1002/ijc.30170
Bushati, N., and Cohen, S. M. (2007). microRNA functions. Annu. Rev. Cell Dev.
Biol. 23, 175–205. doi: 10.1146/annurev.cellbio.23.090506.123406
Chen, C.-Y., Chen, S.-T., Fuh, C.-S., Juan, H.-F., and Huang, H.-C.
(2011). Coregulation of transcription factors and microRNAs in human
transcriptional regulatory network. BMC Bioinformatics 12(Suppl. 1):S41.
doi: 10.1186/1471-2105-12-S1-S41
Chêne, A., Donati, D., Guerreiro-Cacais, A. O., Levitsky, V., Chen, Q., Falk, K.
I., et al. (2007). A molecular link between malaria and Epstein-Barr virus
reactivation. PLoS Pathog. 3:e80. doi: 10.1371/journal.ppat.0030080
Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in
cancer. Nat. Rev. Genet. 10, 704–714. doi: 10.1038/nrg2634
Dennis, G. Jr., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C.,
et al. (2003). DAVID: Database for Annotation, Visualization, and Integrated
Discovery. Genome Biol. 4:P3. doi: 10.1186/gb-2003-4-5-p3
Di Lisio, L., Sánchez-Beato, M., Gómez-López, G., Rodríguez, M. E., Montes-
Moreno, S., Mollejo, M., et al. (2012). MicroRNA signatures in B-cell
lymphomas. Blood Cancer J. 2:e57. doi: 10.1038/bcj.2012.1
Dweep, H., and Gretz, N. (2015). miRWalk2.0: a comprehensive atlas of
microRNA-target interactions. Nat. Methods 12:697. doi: 10.1038/nmeth.3485
Dweep, H., Sticht, C., Pandey, P., and Gretz, N. (2011). miRWalk–database:
prediction of possible miRNA binding sites by “walking” the genes of three
genomes. J. Biomed. Inform. 44, 839–847. doi: 10.1016/j.jbi.2011.05.002
Faye, A., and Poyet, J.-L. (2010). Targeting AAC-11 in cancer therapy. Expert Opin.
Ther. Targets 14, 57–65. doi: 10.1517/14728220903431077
Francoz, S., Froment, P., Bogaerts, S., De Clercq, S., Maetens, M., Doumont, G.,
et al. (2006). Mdm4 andMdm2 cooperate to inhibit p53 activity in proliferating
and quiescent cells in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 3232–3237.
doi: 10.1073/pnas.0508476103
Frontiers in Microbiology | www.frontiersin.org 11 March 2017 | Volume 8 | Article 501
Oduor et al. MicroRNA and Endemic Burkitt Lymphoma
Friard, O., Re, A., Taverna, D., De Bortoli, M., and Corá, D. (2010).
CircuitsDB: a database of mixed microRNA/transcription factor feed-forward
regulatory circuits in human and mouse. BMC Bioinformatics 11:435.
doi: 10.1186/1471-2105-11-435
Friedländer, M. R., Mackowiak, S. D., Li, N., Chen, W., and Rajewsky, N. (2012).
miRDeep2 accurately identifies known and hundreds of novel microRNA genes
in seven animal clades. Nucleic Acids Res. 40, 37–52. doi: 10.1093/nar/gkr688
Hecht, J. L., and Aster, J. C. (2000). Molecular biology of Burkitt’s lymphoma. J.
Clin. Oncol. 18, 3707–3721. doi: 10.1200/JCO.2000.18.21.3707
Helwak, A., Kudla, G., Dudnakova, T., and Tollervey, D. (2013). Mapping the
humanmiRNA interactome by CLASH reveals frequent noncanonical binding.
Cell 153, 654–665. doi: 10.1016/j.cell.2013.03.043
Hsu, S.-D., Tseng, Y.-T., Shrestha, S., Lin, Y.-L., Khaleel, A., Chou, C.-
H., et al. (2014). miRTarBase update 2014: an information resource for
experimentally validated miRNA-target interactions. Nucleic Acids Res. 42,
D78–D85. doi: 10.1093/nar/gkt1266
Huang, D. W., Sherman, B. T., Tan, Q., Kir, J., Liu, D., Bryant, D., et al. (2007).
DAVID Bioinformatics Resources: expanded annotation database and novel
algorithms to better extract biology from large gene lists. Nucleic Acids Res. 35,
W169–W175. doi: 10.1093/nar/gkm415
Jansson, M. D., and Lund, A. H. (2012). MicroRNA and cancer. Mol. Oncol. 6,
590–610. doi: 10.1016/j.molonc.2012.09.006
Karginov, F. V., and Hannon, G. J. (2013). Remodeling of Ago2-mRNA
interactions upon cellular stress reflects miRNA complementarity and
correlates with altered translation rates. Genes Dev. 27, 1624–1632.
doi: 10.1101/gad.215939.113
Kaymaz, Y., Oduor, C. I., Yu, H., Otieno, J. A., Ong’echa, J. M., Moormann, A.
M., et al. (2017). Comprehensive transcriptome and mutational profiling of
endemic Burkitt lymphoma reveals ebv type-specific differences. Mol. Cancer
Res. doi: 10.1158/1541-7786.mcr-16-0305. [Epub ahead of print].
Kishore, S., Jaskiewicz, L., Burger, L., Hausser, J., Khorshid, M., and Zavolan, M.
(2011). A quantitative analysis of CLIP methods for identifying binding sites of
RNA-binding proteins. Nat. Methods 8, 559–564. doi: 10.1038/nmeth.1608
Kozomara, A., and Griffiths-Jones, S. (2014). miRBase: annotating high confidence
microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68–D73.
doi: 10.1093/nar/gkt1181
Langmead, B. (2010). Aligning short sequencing reads with Bowtie. Curr. Protoc.
Bioinformatics Chapter 11, Unit 11.7. doi: 10.1002/0471250953.bi1107s32
Lee, K. T., Tan, J.-K., Lam, A. K., and Gan, S.-Y. (2016). MicroRNAs serving
as potential biomarkers and therapeutic targets in nasopharyngeal
carcinoma: a critical review. Crit. Rev. Oncol. Hematol. 103, 1–9.
doi: 10.1016/j.critrevonc.2016.04.006
Lee, R. C., Feinbaum, R. L., and Ambros, V. (1993). The C. elegans heterochronic
gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell
75, 843–854. doi: 10.1016/0092-8674(93)90529-Y
Leroy, K., Haioun, C., Lepage, E., Le Métayer, N., Berger, F., Labouyrie, E., et al.
(2002). p53 gene mutations are associated with poor survival in low and low-
intermediate risk diffuse large B-cell lymphomas. Ann. Oncol. 13, 1108–1115.
doi: 10.1093/annonc/mdf185
Li, J., Fu, R., Yang, L., and Tu, W. (2015). miR-21 expression predicts
prognosis in diffuse large B-cell lymphoma. Int. J. Clin. Exp. Pathol. 8,
15019–15024.
Li, Z., Chen, X., Li, L., Liu, S., Yang, L., Ma, X., et al. (2012). EBV encoded
miR-BHRF1-1 potentiates viral lytic replication by downregulating host
p53 in nasopharyngeal carcinoma. Int. J. Biochem. Cell Biol. 44, 275–279.
doi: 10.1016/j.biocel.2011.11.007
Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2−11CT method. Methods 25,
402–408. doi: 10.1006/meth.2001.1262
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005).
MicroRNA expression profiles classify human cancers. Nature 435, 834–838.
doi: 10.1038/nature03702
Ma, J., Nie, K., Redmond, D., Liu, Y., Elemento, O., Knowles, D. M., et al.
(2016). EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV
lymphomagenesis. Leukemia 30, 594–604. doi: 10.1038/leu.2015.285
Magrath, I. T. (1991). African Burkitt’s Lymphoma: history, biology,
clinical features, and treatment. J. Pediatr. Hematol. Oncol. 13:222.
doi: 10.1097/00043426-199122000-00019
Marabita, F., de Candia, P., Torri, A., Tegnér, J., Abrignani, S., and Rossi,
R. L. (2016). Normalization of circulating microRNA expression data
obtained by quantitative real-time RT-PCR. Brief. Bioinform. 17, 204–212.
doi: 10.1093/bib/bbv056
Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput
sequencing reads. EMBnet. J 17, 10–12. doi: 10.14806/ej.17.1.200
Mbulaiteye, S. M., Biggar, R. J., Bhatia, K., Linet, M. S., and Devesa, S. S. (2009).
Sporadic childhood Burkitt lymphoma incidence in the United States during
1992–2005. Pediatr. Blood Cancer 53, 366–370. doi: 10.1002/pbc.22047
Miyazaki, T., Kato, H., Nakajima, M., Sohda, M., Fukai, Y., Masuda, N., et al.
(2003). FAK overexpression is correlated with tumour invasiveness and lymph
node metastasis in oesophageal squamous cell carcinoma. Br. J. Cancer 89,
140–145. doi: 10.1038/sj.bjc.6601050
Moormann, A. M., and Bailey, J. A. (2016). Malaria - how this parasitic infection
aids and abets EBV-associated Burkitt lymphomagenesis. Curr. Opin. Virol. 20,
78–84. doi: 10.1016/j.coviro.2016.09.006
Moormann, A. M., Chelimo, K., Sumba, O. P., Lutzke, M. L., Ploutz-Snyder,
R., Newton, D., et al. (2005). Exposure to holoendemic malaria results in
elevated Epstein-Barr virus loads in children. J. Infect. Dis. 191, 1233–1238.
doi: 10.1086/428910
Mulama, D. H., Bailey, J. A., Foley, J., Chelimo, K., Ouma, C., Jura, W. G. et al.
(2014). Sickle cell trait is not associated with endemic Burkitt lymphoma: an
ethnicity and malaria endemicity-matched case-control study suggests factors
controlling EBV may serve as a predictive biomarker for this pediatric cancer.
Int. J. Cancer 134, 645–653. doi: 10.1002/ijc.28378
Murray, B. S., Choe, S. E., Woods, M., Ryan, T. E., and Liu, W. (2010). An in silico
analysis of microRNAs: mining the miRNAome. Mol. Biosyst. 6, 1853–1862.
doi: 10.1039/c003961f
Mwanda, O. W., Rochford, R., Rainey, J., and Wilson, M. L. (2004). Challenges
in the epidemiological and clinical aspects of Burkitt’s lymphoma in Kenya:
linking evidence and experience. East Afr. Med. J. 81(8 Suppl.), S111–S116.
doi: 10.4314/eamj.v81i8.9215
Natarajan, M., Stewart, J. E., Golemis, E. A., Pugacheva, E. N., Alexandropoulos,
K., Cox, B. D., et al. (2006). HEF1 is a necessary and specific downstream
effector of FAK that promotes the migration of glioblastoma cells. Oncogene
25, 1721–1732. doi: 10.1038/sj.onc.1209199
Navari, M., Fuligni, F., Laginestra, M. A., Etebari, M., Ambrosio, M. R.,
Sapienza, M. R., et al. (2014). Molecular signature of Epstein Barr virus-
positive Burkitt lymphoma and post-transplant lymphoproliferative disorder
suggest different roles for Epstein Barr virus. Front. Microbiol. 5:728.
doi: 10.3389/fmicb.2014.00728
Noh, K. H., Kim, S.-H., Kim, J. H., Song, K.-H., Lee, Y.-H., Kang, T. H., et al. (2014).
API5 confers tumoral immune escape through FGF2-dependent cell survival
pathway. Cancer Res. 74, 3556–3566. doi: 10.1158/0008-5472.CAN-13-3225
Ogwang, M. D., Bhatia, K., Biggar, R. J., and Mbulaiteye, S. M. (2008). Incidence
and geographic distribution of endemic Burkitt lymphoma in northern Uganda
revisited. Int. J. Cancer 123, 2658–2663. doi: 10.1002/ijc.23800
Onnis, A., De Falco, G., Antonicelli, G., Onorati, M., Bellan, C., Sherman, O., et al.
(2010). Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
PLoS ONE 5:e12960. doi: 10.1371/journal.pone.0012960
Petillo, D., Kort, E. J., Anema, J., Furge, K. A., Yang, X. J., and Teh, B. T.
(2009). MicroRNA profiling of human kidney cancer subtypes. Int. J. Oncol.
35, 109–114. doi: 10.3892/ijo_00000318
Piccaluga, P. P., Navari, M., De Falco, G., Ambrosio, M. R., Lazzi, S.,
Fuligni, F., et al. (2016). Virus-encoded microRNA contributes to the
molecular profile of EBV-positive Burkitt lymphomas. Oncotarget 7, 224–240.
doi: 10.18632/oncotarget.4399
Piriou, E., Kimmel, R., Chelimo, K., Middeldorp, J. M., Odada, P. S., Ploutz-
Snyder, R., et al. (2009). Serological evidence for long-term Epstein-Barr virus
reactivation in children living in a holoendemic malaria region of Kenya. J.
Med. Virol. 81, 1088–1093. doi: 10.1002/jmv.21485
Reynaldi, A., Schlub, T. E., Chelimo, K., Sumba, P. O., Piriou, E., Ogolla, S.,
et al. (2016). Impact of Plasmodium falciparum coinfection on longitudinal
Epstein-Barr virus kinetics in kenyan children. J. Infect. Dis. 213, 985–991.
doi: 10.1093/infdis/jiv525
Robinson, M. D., McCarthy, D. J., and Smyth, G. K. (2010). edgeR: a Bioconductor
package for differential expression analysis of digital gene expression data.
Bioinformatics 26, 139–140. doi: 10.1093/bioinformatics/btp616
Frontiers in Microbiology | www.frontiersin.org 12 March 2017 | Volume 8 | Article 501
Oduor et al. MicroRNA and Endemic Burkitt Lymphoma
Ruike, Y., Ichimura, A., Tsuchiya, S., Shimizu, K., Kunimoto, R., Okuno,
Y., et al. (2008). Global correlation analysis for micro-RNA and mRNA
expression profiles in human cell lines. J. Hum. Genet. 53, 515–523.
doi: 10.1007/s10038-008-0279-x
Sample, J., Brooks, L., Sample, C., Young, L., Rowe, M., Gregory, C., et al.
(1991). Restricted Epstein-Barr virus protein expression in Burkitt lymphoma
is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation
site. Proc. Natl. Acad. Sci. U.S.A. 88, 6343–6347. doi: 10.1073/pnas.88.
14.6343
Sethupathy, P., Corda, B., and Hatzigeorgiou, A. G. (2006). TarBase: a
comprehensive database of experimentally supported animal microRNA
targets. RNA 12, 192–197. doi: 10.1261/rna.2239606
Seto, E., Moosmann, A., Grömminger, S., Walz, N., Grundhoff, A., and
Hammerschmidt, W. (2010). Micro RNAs of Epstein-Barr virus promote cell
cycle progression and prevent apoptosis of primary human b cells. PLoS Pathog.
6:e1001063. doi: 10.1371/journal.ppat.1001063
Song, G., Cho, W. C., Gu, L., He, B., Pan, Y., and Wang, S. (2014). Increased
CD59 protein expression is associated with the outcome of patients with
diffuse large B-cell lymphoma treated with R-CHOP. Med. Oncol. 31:56.
doi: 10.1007/s12032-014-0056-y
Sonoda, Y., Matsumoto, Y., Funakoshi, M., Yamamoto, D., Hanks, S. K., and
Kasahara, T. (2000). Anti-apoptotic role of focal adhesion kinase (FAK).
Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the
overexpression of FAK in a human leukemic cell line, HL-60. J. Biol. Chem. 275,
16309–16315. doi: 10.1074/jbc.275.21.16309
Sun, Z., Yang, P., Aubry, M.-C., Kosari, F., Endo, C., Molina, J., et al.
(2004). Can gene expression profiling predict survival for patients with
squamous cell carcinoma of the lung?Mol. Cancer 3:35. doi: 10.1186/1476-459
8-3-35
van den Berg, A., Kroesen, B.-J., Kooistra, K., de Jong, D., Briggs, J., Blokzijl,
T., et al. (2003). High expression of B-cell receptor inducible gene BIC in
all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer 37, 20–28.
doi: 10.1002/gcc.10186
Vereide, D. T., Seto, E., Chiu, Y.-F., Hayes, M., Tagawa, T., Grundhoff, A., et al.
(2014). Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 33,
1258–1264. doi: 10.1038/onc.2013.71
Wang, Y.-P., and Li, K.-B. (2009). Correlation of expression profiles between
microRNAs and mRNA targets using NCI-60 data. BMC Genomics 10:218.
doi: 10.1186/1471-2164-10-218
You, T., Hu, W., Ge, X., Shen, J., and Qin, X. (2011). Application of a
novel inhibitor of human CD59 for the enhancement of complement-
dependent cytolysis on cancer cells. Cell. Mol. Immunol. 8, 157–163.
doi: 10.1038/cmi.2010.35
Young, L. S., and Murray, P. G. (2003). Epstein–Barr virus and oncogenesis: from
latent genes to tumours. Oncogene 22, 5108–5121. doi: 10.1038/sj.onc.1206556
Yousef, M., and Allmer, J., (eds.). (2014). MiRNomics: MicroRNA Biology and
Computational Analysis. (New York, NY: Humana Press).
Zhang, H.-M., Kuang, S., Xiong, X., Gao, T., Liu, C., and Guo, A.-Y. (2015).
Transcription factor and microRNA co-regulatory loops: important regulatory
motifs in biological processes and diseases. Brief. Bioinform. 16, 45–58.
doi: 10.1093/bib/bbt085
Zheng, Z., Li, X., Zhu, Y., Gu, W., Xie, X., and Jiang, J. (2016). Prognostic
significance of MiRNA in patients with diffuse large B-Cell lymphoma: a
meta-analysis. Cell. Physiol. Biochem. 39, 1891–1904. doi: 10.1159/000447887
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Oduor, Movassagh, Kaymaz, Chelimo, Otieno, Ong’echa,
Moormann and Bailey. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 13 March 2017 | Volume 8 | Article 501
